



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

H/

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/671,723	09/26/2003	Christi Kosogof	7131.US.01	9278
23492	7590	11/03/2004	EXAMINER	
ROBERT DEBERARDINE ABBOTT LABORATORIES 100 ABBOTT PARK ROAD DEPT. 377/AP6A ABBOTT PARK, IL 60064-6008			COVINGTON, RAYMOND K	
		ART UNIT		PAPER NUMBER
		1625		
DATE MAILED: 11/03/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/671,723	KOSOGOF ET AL.	
	Examiner	Art Unit	
	Raymond Covington	1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 20 February 2004.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-12 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-12 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 2/20/04.
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Stevens et al WO 98/30550 or Stevens et al WO 88/04293 in view of Spohr et al US 6,410,729.

Stevens et al '550 teach phenylpyrimidine compounds of the type recited and their use as anti-cancer agents. See, for example, claim 1 formula (I) where R⁴ is alkoxy, R³ is C₆ alkyl, such as cyclohexyl alkyl and R⁵ in nitro. Steven et al '293 teach other analogous phenylpyrimidine compounds having other activities such as antipsoriatic. Patentees differ from the claimed invention in that they do not teach, for example, rings other than phenyl, corresponding to applicants' formula (I) ring "A". They likewise do not teach treating, e.g., anorexia, obesity or diabetes. However, Spohr et al '729 teach analogous substituted pyrimidine compounds with other substituents, such as heterocyclic "A" rings and treatments such as diabetes. See, for example column 4 lines 20-65, column 19 listing of various compounds, Table 1 and column 2 lines 10-19. Note in particular the definition for R₁₁. It would have been obvious to one of ordinary skill in the art the

structurally analogous compounds of Stevens et al to obtain compounds of the claimed invention in light of the teachings of Spohr et al as the results, compounds with an enhanced range of utilities, would not have been unexpected.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 6-10 and 12 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The nature of the invention: The nature of the invention is a method for treating disorders regulated by ghrelin receptors, claims 6,7,9,10, a method of treating of anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus, claims 8 and 12.

The state of the prior art: The state of the prior art is that it involves screening in vitro to determine which compounds exhibit ghrelin receptor regulation (i.e. what compounds can treat which specific disease). There is no absolute predictability even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face.

The predictability in the art: It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. In re Fisher, 427 F. 2d 833, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. In the instant case, the instantly claimed invention is highly unpredictable since one skilled in the art would recognize that in regards to the therapeutic effects of all diseases, whether or not the compounds of claims 1-5 would make a difference in the treatment of a given disease. It is not seen where the instant specification adequately describes the nexus between ghrelin receptors and a useful treatment of a single disease, condition or cancer. The specification does not

adequately describe what is meant by regulating ghrelin receptors. Is it agonistic or antagonistic? .

The presence or absence of working examples: There are insufficient exemplifications to support the prevention or treatment of all known cancers diseases and conditions regulated by ghrelin receptors.

The amount of direction or guidance present: The specification does not seem to enable a correlation between ghrelin receptors and the treatment of all cancers, diseases and conditions.

The breadth of the claims: The claims are drawn to the treatment of all cancers, diseases and conditions using compounds of claim 1. There are many different types of cancers known by those skilled in the art. There are many different types of eating disorders, some being psychological, falling within the scope of the claims. The claimed method also discloses treating both anorexia and obesity with the same compound with no indication of whether the same dosage amount would produce the same effect in the treatment of both conditions.

The quantity of experimentation needed: The quantity of experimentation needed is undue. One skilled in the art would need to determine what cancers, diseases or conditions out of all known diseases would be benefited by using

the compounds of claim 1 and then would further need to determine which of the claimed compounds would provide treatment of the disease. The obstacles to non in vivo therapeutic approaches are well documented in the literature.

See, for example, Huff {J. Med. Chem. 34(8) 1991, p. 2305-2314} on page 2314.

The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any treatment or any therapeutic regimen on its face. In order to provide proof of utility either clinical in vivo or in vitro data correlative to in vivo applicability or a combination of these can be used. However, the data must be such as to convince one of ordinary skill in the art that the proposed utility is sufficiently established as set forth in full, clear and exact terms in the disclosure. When the utility is directed to humans, the data must generally be clinical, however, adequate animal data would be acceptable in those instances wherein one of ordinary skill in the art would accept correlation to human utility. Thus, in order to rely on animal data, there must exist an art recognized animal model for testing purposes. In re Hartop, 311 F.2d 249, 135 USPQ 419 (CCPA 1962).

The level of the skill in the art: The level of skill in the art is high.

However, due to the unpredictability in the pharmaceutical art, it is noted that each embodiment of the invention is required to be individually assessed for physiological activity. As a result necessitating one of ordinary skill to perform an exhaustive search for which cancers, diseases or conditions can be treated by which compounds of claim 1 in order to practice the claimed invention.

Genentech Inc. v. Novo Nordisk A/S (CA FC) 42 USPQ2d 1001, states that "a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion" and "[p]atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable".


Therefore, in view of the Wands factors and In re Fisher (CCPA 1970) discussed above, to practice the claimed invention herein, one of ordinary skill in the art would have to engage in undue experimentation to test which cancers, diseases or conditions can be treated by the compounds of the instant claims, with no assurance of success.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Raymond Covington whose telephone number is (571) 272-0681. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, C. Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Raymond Covington
Examiner
Art Unit 1625

RKC